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ABSTRACT
With the proliferation of outcome measures in the literature, 
many of which lack documentation of sufficient psychometric 
properties to justify use, it is difficult to document patient change 
or demonstrate effectiveness of interventions. The goal of the 
Section on Research’s EDGE (Evaluation Database to Guide 
Effectiveness) Task Force is to facilitate identification of valid 
and reliable tests and measures that reflect clinically important 
outcomes and are responsive to change for standard use across 
selected patient groups. This paper lays the groundwork for 
understanding the work of the Oncology Section’s Breast Cancer 
EDGE Task Force on clinical measures of shoulder function 
including range of motion and muscle length, upper extremity 
function, and scapular position and movement, as reported in the 
3 papers that follow.
INTRODUCTION
The importance of outcome measurements to assess effec-
tiveness of interventions has long been recognized.  The physical 
therapy profession has answered this need with the development 
of many such measures.  A search of the term outcomes measure-
ment in PubMed1 yielded 12,138 hits. A search of the term 
outcomes measurements in physical therapy yielded 633 hits. As 
the variety of outcomes measurements proliferated, two concerns 
emerged. The first concern was over the quality of the measure-
ments that led to an increased emphasis on ascertaining and docu-
menting the psychometric properties of tests and measurements. 
In 1993, the American Physical Therapy Association (APTA) 
published the Primer on Measurement: An Introductory Guide to 
Measurement Issues2 to educate researchers and clinicians alike 
on important considerations in development and use of tests and 
measures. Many journals now require that outcomes reported in 
submitted papers include information on references that support 
the psychometric properties and clinical utility of the measures.
The second concern in the proliferation of tests and measures 
is the variety and disparate nature of the tests and measures, 
even across similar outcomes. The desirability of reducing the 
number of tests and measures being used within certain domains 
and promoting select common or ‘standard’ measures became 
evident. Deyo et al3 advocated for standardization in measure-
ment of patient outcomes in order to:
•   improve comparability of results among clinical studies;
•   improve comparability of baseline patient characteristics 
among clinical studies;
•   facilitate meta-analysis;
•   facilitate cost-effectiveness analysis by creating an accepted 
metric for effectiveness;
•   encourage more complete reporting of relevant outcomes;
•   facilitate conduct of multicenter studies;
•   facilitate design and review of manuscripts, publications, 
research proposals; and
•   avoid ‘reinventing the wheel.’
EDGE TASK FORCE BACKGROUND
In an effort to foster standardization of outcomes measure-
ments in physical therapy, the APTA’s Section on Research 
supported the formation of a task force led by Edelle Field-
Fote, PT, PhD.  The EDGE (Evaluation Database to Guide 
Effectiveness) Task Force brought together experts in evaluation 
of tests and measures and in examination-based classification 
of patients at APTA’s Combined Sections Meeting in 2006. The 
group agreed that standardization of outcomes in a particular 
domain was a necessary step in the process of accumulating 
evidence on the effectiveness of a treatment approach in that 
domain.  According to Field Fote et al,4 “the bottom line is 
that evidence of intervention effectiveness depends on, among 
other things, common use of valid and reliable tests/measures 
that reflect clinically important outcomes and are responsive to 
change.” The EDGE Task Force goals were to:
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•   establish a framework to facilitate the evaluation of 
outcome measures,
•   assist stakeholder groups (ie, Section Research Chairs, 
SIGs, Specialty Councils) in evaluating outcome measures 
within their practice/content areas, and 
•   assist in promoting the use of a core set. 
Using a literature and consensus-based iterative process, the 
EDGE Task Force developed a form for evaluation of a selected 
outcome measure.  The purpose of the form was to provide crite-
ria important in determining whether a measure is appropriate 
as a ‘standardized’ assessment tool and suitable for inclusion in 
a ‘core set’ in a particular clinical domain.  Through use of the 
form, assessment of an outcome measure would be thorough and 
consistent among evaluators and across tools.
After completion of its assessment form, the EDGE Task 
Force expanded its membership to include representatives from 
the clinical sections of the APTA, with the goal of having the 
Sections carry the work forward to their particular areas of 
interest.  The Neurology Section was the first Section to apply 
EDGE assessment to a practice area.  The StrokEDGE Task 
Force led by Jane Sullivan, PT, DHS, and Genevieve Pinto-Zipp, 
PT, EdD, reviewed outcomes used in individuals who had a 
stroke. This Task Force also developed a 4-point ordinal scale to 
rank their recommendations for each outcome measure5 (Table 
1).  StrokEDGE disseminated its recommendations through the 
Neurology Section Web site.5 
As part of the ongoing progression of the EDGE Task 
Force work, the APTA’s Oncology Section formed the Breast 
Cancer EDGE Task Force in 2010 under the leadership of Laura 
Gilchrist, PT, PhD.  The working group employed a similar 
strategy to that of StrokEDGE, using the domains of the World 
Health Organization’s International Classification of Functioning, 
Disability and Health (ICF).6 The group agreed on 8 subdomains 
under Body Structure and Function and 11 subdomains under 
Activities and Participation that were appropriate to individuals 
who had been treated for breast cancer.  The group also assessed 
the original EDGE assessment form and the StrokEDGE form. 
A few additional modifications were made to include criteria 
that were relevant to measurement tools that would be evaluated 
for use in the cancer population.  The final CancerEDGE form 
approved for use by the group can be found in the Appendix. 
The first practice area the Breast Cancer EDGE group chose 
was outcome measures relevant to shoulder and upper quarter 
function in individuals treated for breast cancer.  Measurements 
of lymphedema were excluded because outcomes related to 
lymphedema were determined to be a separate subdomain.  The 
Shoulder Subgroup is the first Oncology EDGE group to examine 
relevant outcome measures for the cancer population.
SHOULDER DYSFUNCTION ASSOCIATED WITH 
TREATMENT FOR BREAST CANCER
It is now widely acknowledged that various elements in the 
treatment for breast cancer can produce both early (less than one 
year) and late (greater than one year) adverse effects on shoulder 
function, including range of motion (ROM) strength deficits, and 
reported declines in quality of life. Furthermore, effects of treat-
ment are considered to be multifactorial, including but not neces-
sarily limited to type of surgery, degree of axillary node resection, 
radiation, prior shoulder problems, and age.7-14  Such effects 
have been found after treatment when comparing pre-op to post-
op values, when comparing involved to uninvolved sides, and 
when comparing those treated for breast cancer to an unaffected 
control group.15-19  Documenting the incidence and magnitude of 
dysfunction or identifying treatment factors that increase the risk 
for dysfunction has been challenging because of the variety of 
assessment strategies used in different studies. 
The absence of standardized measurements for shoulder 
dysfunction limits the ability to compare study findings across 
treatment factors and populations.11,20  In their systematic review, 
Levangie and Drouin17 looked at studies that compared several 
treatment factors, including chest wall radiation to more extensive 
radiation, and axillary node clearance to sentinel node biopsy. 
They found that the magnitudes of effect varied across studies 
dramatically from small (standardized effect sizes of ≤ 0.20 or 
odds ratios near 1.0) to substantial (standardized effect sizes 
well in excess of 0.80 or odds ratios of 2.0-3.0 or more).  The 
variability in prevalence or magnitude of shoulder dysfunction 
may be attributed in part to the diversity of outcome measures 
and the variety of methods by which even similar outcomes were 
assessed and reported in the literature.  Levangie and Drouin17 
noted that 10 of the 22 reviewed studies used patient self-report 
of loss of strength, ROM, or functional ability.  Two other studies 
used simple observation of impairments such as ROM.  In most 
of these studies, the data were then dichotomized into present or 
absent.  Of the studies that measured ROM objectively, 7 reported 
actual ranges, while 5 dichotomized their findings based on 
losses of as little as 10° of motion.17  
Shoulder impairments and functional limitations post-breast 
cancer treatment may not only affect function and quality of life, 
but may also increase the potential for subsequent pathology. 
Two studies using 3-dimensional motion analysis both came to 
Table 1.  StrokeEDGE Rating Scale1
4 Highly Recommend
Highly recommended; the outcome measure has 
excellent psychometric properties and clinical 
utility.
3 Recommend Recommended; the outcome measure has good psychometric properties and good clinical utility.
2 
Unable to 
Recommend at 
this time
Unable to recommend at this time; there is insuf-
ficient information to support a recommendation 
of this outcome measure.
1 Do not Recommend
Not recommended. The outcome measure has 
poor psychometric properties and/or poor clinical 
utility.
1 http://neuropt.org/go/healthcare-professionals/neurology-section-outcome-
measures-recommendations
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the conclusion that individuals treated for breast cancer were 
more likely to have internally rotated scapula.15,21 An increase in 
scapular internal rotation may elevate the risk for impingement 
problems.22  Yang et al23 found that 7.1% of his breast cancer 
cohort had symptoms of rotator cuff disease at 12 months after 
surgery.  If impairments and limitations that place a person 
treated for breast cancer at increased risk for later pathology can 
be identified, these impairments can be addressed with interven-
tions targeted at interrupting the causal chain of events.  Evidence 
does exist that physical therapy treatment can improve shoulder 
function in individuals treated for breast cancer.24  We still do not 
have the tools, however, to demonstrate our ability to prevent 
dysfunction or future pathology through surveillance. 
ONCOLOGY SECTION TASK FORCE ON BREAST 
CANCER OUTCOMES: CLINICAL MEASURES OF 
UPPER EXTREMITY FUNCTION
The evidence to date indicates that individuals treated for 
breast cancer may experience upper extremity functional limita-
tions 12 months or more after treatment,17 that long-term shoul-
der/arm problems in this population are significantly associated 
with poor quality of life,18 that shoulder limitations may lead to 
pathology over time,23 and that these sequelae might be modified 
with physical therapy surveillance and intervention.24  To truly 
understand how and when to intervene and what interventions 
are effective in preventing or resolving shoulder dysfunction in 
the breast cancer population, valid and reliable measures must be 
available for the purposes described by Deyo et al.3 
The Shoulder Subgroup of the Breast Cancer EDGE Task 
Force was charged with reviewing the literature and assessing 
clinical measures of the upper extremity.  The group divided 
relevant outcomes into 3 categories: scapular measures (body 
structure and function), shoulder/glenohumeral measures (body 
structure and function), and upper extremity function (activity/
participation measures).  Three working groups were formed, 
each taking one of the 3 categories of clinical measures. After 
completing preliminary work, the group determined that a 
modification of the StrokEDGE 4-point recommendation scale 
was warranted.  Many tests and measurements thought to be 
potentially appropriate for use in the breast cancer population 
were designed for other patient populations.  Because there was 
concern that tests and measures might behave differently in the 
breast cancer population, the recommendation scale was revised 
to reflect whether psychometric properties for a measure had 
been obtained or used in studies with individuals treated for 
breast cancer (Table 2).
 At the Combined Sections Meeting in 2012, the Breast 
Cancer EDGE Task Force’s subgroup on Clinical Measures of 
Upper Extremity Function presented its findings. The presenters 
asked Rehabilitation Oncology for the opportunity to also present 
their findings to the entire Oncology Section. The goal of publish-
ing these papers is to disseminate the EDGE recommendations 
on measures that can or should be used for individuals treated 
for breast cancer. Each paper also includes existing measures that 
require validation or further validation in the breast cancer popu-
lation, as well as identification of areas where clinically relevant 
measures of upper extremity are still quite inadequate.  Until 
valid, reliable, and clinically useful measures of upper extremity 
function are both available and in widespread use in those treated 
for breast cancer, we will be challenged in our ability to defini-
tively demonstrate the effects of breast cancer on function and 
quality of life, as well as to justify the need for routine surveil-
lance and periodic intervention in this population. 
REFERENCES
1.     PubMed.  http://www.pubmed.gov. Accessed August 19, 2012.
2.     Rothstein J, Ecternach J. Primer on Measurement: An 
Introductory Guide to Measurement Issues. Alexandria, VA: 
American Physical Therapy Association; 1993.
3.     Deyo RA, Battie M, Beurskens AJ, et al. Outcome measures 
for low back pain research. A proposal for standardized use. 
Spine. 1998;23(18):2003-2013.
4.     Field Fote E, Levangie PK, Craik R. Towards Optimal 
Practice – How Can Students Contribute? Student Assembly 
Pulse (Newsletter of the Student Assembly of the APTA). 
March ed: American Physical Therapy Association; 2007.
5.     StrokEDGE.  http://www.neuropt.org/go/healthcare-profes-
sionals/neurology-section-outcome-measures-recommen-
dations/stroke/strokedge-documents. Accessed August 19, 
2012.
6.     International Classification of Functioning, Disability and 
Health.  http://www.who.int/classifications/icf/en/. Accessed 
August 19, 2012.
7.     Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. 
Treatment of morbidity associated with the management 
of the axilla in breast-conserving therapy. Acta Oncol. 
2000;39(3):349-354.
Table 2.  Breast Cancer EDGE Rating Scale
4 Highly Recommend
Highly recommended; the outcome has good 
psychometric properties and good clinical utility; 
the measure has been used in research on indi-
viduals with or post breast cancer.
3 Recommend
Recommended; the outcome measure has good 
psychometric properties and good clinical utility; 
no published evidence that the measure has been 
applied to research on individuals with or post 
breast cancer.
2A 
Unable to 
Recommend at 
this time
Unable to recommend at this time; there is insuf-
ficient information to support a recommendation 
of this outcome measure; the measure has been 
used in research on individuals with or post breast 
cancer.
2B
Unable to 
Recommend at 
this time
Unable to recommend at this time; there is insuf-
ficient information to support a recommendation 
of this outcome measure; no published evidence 
that the measure has been applied to research on 
individuals with or post breast cancer.
1 Do not Recommend
Poor psychometrics &/or poor clinical utility 
(time, equipment, cost, etc.).
Rehabilitation Oncology
Vol. 30, No. 4, 2013
9
8.     Rietman J, Dijkstra P, Debreczeni R, Geertzen J, Robinson D, 
De Vries J. Impairments, disabilities and health related qual-
ity of life after treatment for breast cancer: a follow-up study 
2.7 years after surgery. Disabil Rehabil. 2004;26(2):78-84.
9.     Satariano WA. Aging, comorbidity, and breast cancer survival: 
an epidemiologic view. Adv Exp Med Biol. 1993;330:1-11.
10.   Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM. 
Prognosis of the upper limb following surgery and radiation 
for breast cancer. Breast Cancer Res Treat. 2008;110(1):19-
37.
11.   Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel 
lymph node biopsy (SLN) alone versus SLN and completion 
axillary lymph node dissection after breast cancer surgery: 
a prospective Swiss multicenter study on 659 patients. Ann 
Surg. 2007;245(3):452-461.
12.   Freitas-Silva R, Conde DM, de Fretias-Junior R, Martinez 
EZ. Caomparison of quality of life, satisfaction with surgery 
and shoulder-arm morbidity in breast cancer survivors 
submitted to breast-conserving therapy or mastectomy 
followed by immediate breast reconstruction. Clinics (San 
Paolo). 2010;65(8):781-787.
13.   Johansson K, Ingvar C, Albertsson M, Ekdahl C. Arm 
lymphoedema, shoulder mobility and muscle strength after 
breast cancer treatment -- a prospective 2-year study. Adv 
Physiother. 2001;3(2):55-66.
14.   Blomqvist L, Stark B, Engler N, Malm M. Evaluation of arm 
and shoulder mobility and strength after modified radical 
mastectomy and radiotherapy. Acta Oncol. 2004;43(3):280-
283.
15.   Borstad JD, Szucs KA. Three-dimensional scapula kinemat-
ics and shoulder function examined before and after surgical 
treatment for breast cancer. Hum Mov Sci. May 6, 2011.
16.   Harrington S, Padua D, Battaglini C, et al. Comparison of 
shoulder flexibility, strength, and function between breast 
cancer survivors and healthy participants. J Cancer Surviv. 
2011;5(2):167-174.
17.   Levangie PK, Drouin J. Magnitude of late effects of breast 
cancer treatments on shoulder function: a systematic review. 
Breast Cancer Res Treat. 2009;116(1):1-15.
18.   Nesvold IL, Reinertsen KV, Fossa SD, Dahl AA. The relation 
between arm/shoulder problems and quality of life in breast 
cancer survivors: a cross-sectional and longitudinal study. J 
Cancer Surviv. 2011;5(1):62-72.
19.   Rietman JS, Dijkstra PU, Hoekstra HJ, et al. Late morbidity 
after treatment of breast cancer in relation to daily activities 
and quality of life: a systematic review. Eur J Surg Oncol. 
2003;29(3):229-238.
20.   Bentzen SM, Dische S. Morbidity related to axillary 
irradiation in the treatment of breast cancer. Acta Oncol. 
2000;39(3):337-347.
21.   Shamley D, Srinaganathan R, Oskrochi R, Lascurain-
Aguirrebena I, Sugden E. Three-dimensional scapulotho-
racic motion following treatment for breast cancer. Breast 
Cancer Res Treat. 2009;118(2):315-322.
22.   Seitz AL, McClure PW, Finucane S, Boardman ND, 3rd, 
Michener LA. Mechanisms of rotator cuff tendinopathy: 
intrinsic, extrinsic, or both? Clin Biomech (Bristol, Avon). 
2011;26(1):1-12.
23.   Yang EJ, Park WB, Seo KS, Kim SW, Heo CY, Lim 
JY. Longitudinal change of treatment-related upper limb 
dysfunction and its impact on late dysfunction in breast 
cancer survivors: a prospective cohort study. J Surg Oncol. 
2010;101(1):84-91.
24.   McNeely ML, Campbell K, Ospina M, et al. Exercise interven-
tions for upper-limb dysfunction due to breast cancer treat-
ment. Cochrane Database Syst Rev. 2010;16(6):CD005211.
(Cancer EDGE Task Force Outcome Measure Rating Form 
follows on page 10.)
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Instrument name:
Reviewer:
ICF Domain (check all that apply):       _____body function/structure     _____ activity     _____participation
Type of measure:      _____ performance-based     _____self-report 
Languages available:
Population developed in:
Validated populations: 
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Reliability  (test-retest, intra-rater, inter-rater)
Validity (concurrent, criterion-related, predictive)
Ceiling/ floor effects 
Sensitivity to change (responsiveness, MCID, MDC)
Reference Values for Interpretation
Instrument use
Equipment required
Time to complete
How is the instrument scored?  (eg, total score, subscales, 
etc.)
Level of client participation required (proxy participation?)
Effect of Training (if applicable)
Is this tool appropriate for individual patient decision-making?  Yes  _____     No  _____
(available MDC, MCID, Likelihood ratios?)
Comments:
Availability:
Score Sheets:   _____ Public Domain     _____Available but copyrighted    _____Unavailable
Instructions:    _____ Public Domain     _____Available but copyrighted    _____Unavailable
Computer-based or Web-based scoring available:  ____ yes    _____ no
Purchase price:  
Purchase Contact Info:
Assessment of Overall Usefulness (Primary Reviewer):
Secondary Reviewer Comments:
Overall Task Force Agreement with Recommendations:
Reference List: 
CANCER EDGE TASK FORCE OUTCOME MEASURE RATING FORM 
(Adapted from Neurology Section EDGE form)
